Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 16/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123959 | 0.81 | ENPP2 (0.49) | HTR2ASLC6A4KCNH2ENPP2SLC6A2 | |
| SCHEMBL12260881 | 0.80 | ENPP2 (0.52) | HTR2ASLC6A4KCNH2ENPP2CA1 | |
| SCHEMBL30760847 | 0.80 | AR (0.55) | ENPP2CA1CA2 | |
| SCHEMBL1018126 | 0.79 | ENPP2 (0.49) | ENPP2CA1CA2 | |
| SCHEMBL29427068 | 0.79 | ENPP2 (0.49) | ENPP2CA1CA2 | |
| SCHEMBL15155925 | 0.78 | TTR (0.58) | ENPP2CA1CA2 | |
| SCHEMBL10269952 | 0.77 | CA1 (0.57) | ENPP2CA1CA2HSP90AA1 | |
| SCHEMBL13860477 | 0.77 | HTR2A (0.54) | HTR2ASLC6A4KCNH2HSP90AA1SLC6A2 | |
| SCHEMBL13857896 | 0.77 | HTR2A (0.61) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL23114 | 0.77 | ENPP2 (0.52) | ENPP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | HTR2A 4693/4885SLC6A4 4378/4885KCNH2 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.